If you simply compare the average development times of pharmaceuticals, biotech and medical devices, you will see that medical devices demonstrate the shortest time from conception to market (or rejection). Devices, by virtue of providing, in many cases, a simple mechanical function — flatten atherosclerotic plaque against the lumen (angioplasty), keep it there (stents), close [...]
Excerpt from MedMarket Diligence report #S245, “Worldwide Wound Management, 2007-2016.” See link for more information. Available for purchase online.
Technologies developed and in use for the management of acute and chronic wounds have diversified from traditional dressings, bandages and wound closure techniques to include an increasing number of diverse technologies ranging from tissue engineering, growth [...]
Below is the coverage in the April 2008 issue of MedMarkets.
Ablation: An Energized Market
Demand for Hip and Knee Implants Expected to Increase
MedMarket Outlook: Beyond Technology Innovation: Current and Future Market Forces and Trends
Early Stage Companies: Evalve, ES Vascular, Cardiorobotics, TriVascular
Early Stage Company Financings: Alure Medical, Arbel Medical, Breathe Technologies, CoAxia, IDev Technologies, IlluminOss [...]
¶
Posted 13 May 2008
† P. Driscoll
§
cancer § cardiology § drug § innovation § market data § medtech § nanotech § neurology § obesity § ophthalmology § orthopedic § spine § startups § surgery § tissue engineering § urogenital § wound management
‡
°
Tagged: biotech, cancer, cardiology, drug, innovation, market data, medtech, nanotech, neurology, obesity, ophthalmology, orthopedic, spine, startups, surgery, tissue engineering, urogenital, wound management
We have just updated our “High Growth Medical Technologies” white paper, as we expect to continually do in the immediate future, since the areas with growth keep changing, and new areas keep appearing.
As all white papers should be, it’s free. Here’s the link so you can download it.
bookmark to
¶
Posted 09 April 2008
† P. Driscoll
§
cancer § cardiology § drug § gastroenterology § innovation § market data § medtech § nanotech § neurology § obesity § ophthalmology § orthopedic § spine § startups § surgery § tissue engineering § urogenital § wound management
‡
°
Tagged: biotech, cancer, cardiology, drug, gastroenterology, innovation, market data, medtech, nanotech, neurology, obesity, ophthalmology, orthopedic, spine, startups, surgery, tissue engineering, urogenital, wound management
From the December 2007 edition of MedMarkets
Never before, or so it seems, have there been so many widely different dynamics in medical technology markets that determine whether a company will be successful, or if successful, to what degree. Science, its application in technology, and its commercialization in healthcare has traditionally been driven by a narrow [...]
(From the September 2007 issue of MedMarkets)
Drawing upon the clinical and technology sectors we have addressed in MedMarkets and the Market and Technology Reports of MedMarket Diligence, we have previously identified a number of areas where we see substantial growth in medical technology markets. In our white paper, High Growth Medical Technologies, we note those [...]
¶
Posted 26 September 2007
† P. Driscoll
§
cancer § cardiology § gastroenterology § market data § medtech § nanotech § neurology § obesity § orthopedic § surgery § tissue engineering
‡
°
Tagged: biotech, cancer, cardiology, gastroenterology, market data, medtech, nanotech, neurology, obesity, orthopedic, surgery, tissue engineering
It has already been said that medical technology is getting complicated. Now it’s time to point out that the world is getting strikingly small(er).
Even the youngest startup has to consider market opportunity on a global scale. So a little medtech startup with not much more than a patent (and sometimes not even that) and with [...]
Time was when a device was a device, a drug was a drug and biotech was . . . well, still in R&D. If it walks like a duck, sounds like a duck and looks like a duck, it’s a duck — or is it? You have to make certain that you carefully [...]
Allografts are the main “traditional” orthopaedic biomaterials. This market segment includes bone allografts (fresh, or freeze-dried bone; also demineralized bone) and soft-tissue allografts, including cartilage, tendons and meniscus.
The global market for all allografts was $1.5 billion in 2006, with bone allografts contributing half of that, soft-tissue allografts $500 million, and demineralized bone the remaining [...]
Surgical sealants and fibrin glues are biologically-based products designed to aid in the process of clot formation. Clotting is the first naturally occurring process in wound repair, and affects many subsequent biochemical processes in the wound healing cascade.
During the wounding event, blood from capillaries at the damaged tissue site seeps out and reacts with tissue [...]